1785 Jianghai Road,building No.1
44 articles with Ascletis, Inc.
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
Ascletis Pharma Inc. announces that the board of directors of the Company resolved to change the use of the remaining Net Proceeds from the Global Offering.
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC consists of 200 mg Ravidasvir (RDV) and 400 mg Sofosbuvir (SOF). This phase I brid
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
Ascletis Pharma Inc. announces dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.
Ascletis Pharma Inc. announces that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis drug candidate ASC40 in 34 Chinese subjects has been completed and data indicates that key pharmacokinetic parameters are consistent between subjects in China and in the United States.
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-alcoholic Steatohepatitis (NASH) indication. Ascletis has two additional drug
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose Combination). ASC09 has an unprecedented high genetic barrier to resistance and
10/11/2019Companies strengthen their leadership teams and boards of directors with these appointments.
Ascletis Pharma Inc., an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr. Lindi Tan, Chief Financial Officer, departs the Company
ASC40, an orally bioavailable, first-in-class inhibitor of fatty acid synthase, is currently in a global Phase 2 trial in NASH of which the first patient was dosed in late April, 2019 in the USA.
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
3-V Biosciences, Inc. and Ascletis Pharma Inc. announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN inhibitor TVB-2640 in patients with non-alcoholic steatohepatitis.
Ascletis Pharma Inc. announces that according to the official notifications from Zhejiang Provincial Medical Insurance Bureau, Zhejiang Provincial Department of Finance and Zhejiang Provincial Health Committee, the "Basic Medical Insurance -- Reimbursement-by-disease for outpatients with Hepatitis C" program will be launched in Zhejiang Province.
Ascletis Pharma Inc. and 3-V Biosciences, Inc. jointly announce that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for 3-V Biosciences' FASN inhibitor TVB-2640, a first-in-class, Phase 2-ready drug candidate for non-alcoholic steatohepatitis, in Greater China.
Ascletis Pharma Inc. announces today that Dr. Lindi Tan joins Ascletis as Chief Financial Officer.
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD
Ascletis Pharma Inc. announces today that a phase II / III clinical study of its all-oral HCV treatment (RDV/DNV Regimen) has been selected by AASLD's Scientific Program Committee as a Poster Presentation.
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
Ascletis Pharma Inc. announced today that Mr. Joshua Zhongbao Ling joined Ascletis as Vice President of Finance. Mr. Ling will be responsible for the corporate finance management.
Ascletis Pharma Inc. (1672.HK) announced today Ravidasvir is recommended by the World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection (July 2018) as a future pan-genotypic direct-acting antivirals agent (DAA). Ascletis received the acceptance letter for Ravidasvir new drug application (NDA) from the China Food and Drug Administration (CFDA) on August 1.
Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.
Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA).
The company expects to receive feedback from the China Food and Drug Administration (CFDA) within five business days.